ThinkEquity Upgrades Anadys Pharma (ANDS) to Buy
ANDS Hot Sheet
Rating Summary:0 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
ThinkEquity upgrades Anadys Pharma (Nasdaq: ANDS) from Accumulate to Buy with a $6 price target.
For more analyst ratings on ANDS click here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
For more analyst ratings on ANDS click here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Goldman Sachs Cuts Numbers on Tiffany & Co. (TIF) after Weak Q1, Guidance
- JPMorgan Upgrades Illinois Tool Works (ITW) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
